Known for its blockbusters for infectious disease including Biktarvy (bictegravir/emtricitabine/tenofovir) for HIV and COVID-19 therapeutic Veklury (remdesivir), Gilead Sciences, Inc. is intending to expand its oncology business in Japan in line with similar moves globally.
Gilead Builds Japan Oncology Presence With Trodelvy
Yescarta Also Back In House
Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.
More from Japan
More from Focus On Asia
• By
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
• By
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
• By
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.